Skip to content
hcg-service-hero-1

Insights From Halloran

Halloran Consulting GroupNov 15, 2019 4:24:00 PM4 min read

Operationalizing Complex Clinical Trials

This article was originally published on November 14th, 2019 in Applied Clinical Trials.
Start Reading
Halloran Consulting GroupNov 5, 2019 4:18:00 PM6 min read

A Rare Opportunity 

I attended the NORD 2019 Summit in Washington, DC a few weeks ago. It was my first chance ...
Start Reading
Halloran Consulting GroupJul 15, 2019 4:02:00 PM< 1 min read

Foundation NYC Recap

Halloran was proud to sponsor Foundation NYC, an annual event for entrepreneurs and ...
Start Reading
Halloran Consulting GroupJun 6, 2019 4:14:00 PM5 min read

Maximize Patient Engagement in Rare and Orphan Disease Clinical Trials

While it may seem obvious that clinical trials for rare and orphan disease groups are the ...
Start Reading
Sheila GwizdakMay 17, 2019 11:40:00 AM8 min read

4 Key Ingredients Of A Robust Risk Management Framework

This article was originally published on May 16th, 2019, in Clinical Leader.
Start Reading
Nicole GalloMar 22, 2019 2:02:00 PM4 min read

“If This Is True” – What Does This Mean for Clinical Trials?

On March 19, 2019, the FDA released an Impact Story with implications for nearly everyone ...
Start Reading
Emily MarschokMar 19, 2019 2:39:00 PM1 min read

Reflections on Rare Disease Day 2019

I had the pleasure of attending MassBio’s 2019 Rare Disease Day event – a day which (I ...
Start Reading
Halloran Consulting GroupNov 29, 2018 4:19:00 PM8 min read

Apple Watch Approval Marks Shift In Device Development And Approvals

In September, the U.S. Food and Drug Administration (FDA) approved the Apple Watch’s ...
Start Reading
Nicole GalloNov 22, 2018 5:13:00 PM7 min read

Regulatory And Clinical Strategic Planning For Cell And Gene Therapies

A successful Initial Targeted Engagement for Regulatory Advice on CBER products ...
Start Reading
Halloran Consulting GroupAug 21, 2018 12:21:00 PM3 min read

NIH RAC Changes

The changes to the National Institutes of Health (NIH) Recombinant DNA Advisory Committee ...
Start Reading